
Please try another search
By Caroline Humer
NEW YORK (Reuters) - Moderna (NASDAQ:MRNA) Inc's top scientist said on Tuesday that the vaccine maker has learned how to better recruit from diverse populations for its clinical trials from running its COVID-19 vaccine studies.
Moderna Chief Medical Officer Paul Burton, speaking at the Reuters NEXT conference in New York, said that in 2020 the company needed to slow enrollment in its initial COVID-19 vaccine clinical trial in order to include more people in communities of color.
"We recognized that to get good uptake to get real acceptance, you need to have representation of all sorts of people from different communities," Burton said, noting that the company was eventually able to enroll 37% of its 35,000-person trial from communities of color.
Moderna has worked to match that diverse enrollment in its other ongoing trials, Burton said. He said enrollment of people of color in its Respiratory Syncytial Virus (RSV) and Cytomegalovirus (CMV) vaccine trials was probably over 35%.
Burton also said the company had used new technologies to allow people to take part in studies from home, which he said could help democratize research by reaching even further flung populations.
To view the Reuters NEXT conference live on Nov. 30 and Dec. 1, please click here.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.